BioSpace News Archive

On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD).

ProSomnus, Inc. will report its strong second quarter financial results prior to market open on Thursday, August 3, 2023.

Incannex Healthcare Limited is pleased to announce that Incannex has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/ bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the Company’s proprietary drug product for treatment of obstructive sleep apnoea.

A study published in the International Journal of Pharmaceutics explores the advancement of pharmaceutical oral dosage forms and the feasibility of manufacturing composite tablets with freely tailorable drug release profiles using 3D screen printing (3DSP) technology.

Inovedis GmbH today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for SINEFIX™, a new implant system for the repair of rotator cuff tears.

Tempus today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of cancer patients.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, announces that its contract manufacturer

Critical Path Institute and the Center for Health + Technology at University of Rochester announced the release of two seminal publications about digital health technologies for Parkinson’s.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the publication of preclinical data on soquelitinib, the Company’s ITK inhibitor product candidate, which highlighted the selective inhibition of ITK to potentially enhance anti-tumor immune response to hematologic and solid tumors and provide a novel approach to cancer immunotherapy.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company approved the grant of equity awards to 11 new employees with a grant date of July 3, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.